晨间信号Morning Signal
《新科学家》 第3578期 · 2026年1月17日 · 中文解读

重量级问题

A weighty issue · Alexandra Thompson
约 7 分钟Views在小程序里点播,20 到 60 分钟做好
这篇讲什么
本文探讨了抗肥胖药物市场的现状,并评论了Aimee Donnellan的新书《Off the Scales》,该书讲述了Ozempic等GLP-1药物的开发历程及其对肥胖治疗的影响。
原文开头
With the market for anti-obesity drugs already worth billions, a timely book explores the controversial medicines, finds Alexandra Thompson Book Off the Scales Aimee Donnellan HarperCollins, UK; St. Martin’s Press, US I’M NOT looking to get into a debate about how well old comedy shows have aged. But when I rewatch Friends, I feel uncomfortable at how Monica is depicted as a younger person: not just overweight, but laughable, greedy, lazy and, frankly, unattractive. More than two decades on from the final episode of the iconic series, I am optimistic that the tide is turning on how society responds to people who are overweight or have obesity. And I wonder if some of that is due to drugs like Ozempic. …
摘自《新科学家》(New Scientist)第3578期 · 2026年1月17日,Alexandra Thompson。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。
晨间信号小程序码
微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号
同期其他文章